

Date: September 11, 2026

To,
Sr. General Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

BSE Scrip Code: 544319

To,
Sr. General Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

NSE Symbol: SENORES

Dear Sir/Madam,

Subject.: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015- Successful Completion of USFDA Inspection

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to announce that the United States Food and Drug Administration (USFDA) has successfully completed its inspection at the manufacturing facility of Apnar Pharma Private Limited, Subsidiary Company, situated at Vadodara, from Monday, September 07, 2026, till Friday, September 11, 2026 with one minor procedural and no GMP-related observation. The Subsidiary Company will submit its response within the stipulated timeframe.

We request you to take the above information on record.

Thanking you.

For Senores Pharmaceuticals Limited

Shilpa Sharma
Company Secretary and Compliance Officer
ICSI Membership No.: A34516

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com
W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263